Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06153433
Other study ID # 4-2023-0589
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 6, 2023
Est. completion date August 2024

Study information

Verified date November 2023
Source Yonsei University
Contact Jung-Sun Kim
Phone +82-2-2228-8457
Email kjs1218@yuhs.ac
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of study is to evaluate the efficacy and safety of the new generic formulation (rosuvastatin orally disintegrating tablet (SUVARO®ODT) in patients with dyslipidemia.


Description:

STUDY OBJECTIVES: The aim of study is to evaluate the efficacy and safety of the new generic formulation (rosuvastatin orally disintegrating tablet (SUVARO®ODT) in patients with dyslipidemia. Also, this study is designed to observe patients' preference and adherence for SUVARO®ODT. HYPOTHESIS: We hypothesized that there will be no difference in LDL-C lowering efficacy of the two formulations (SUVARO®ODT 10-mg or rosuvastatin Immediate-release tablet (IR) 10-mg). STUDY DESIGN: This is a randomized, multicenter, open-label, two-period crossover study with 112 enrolled patients. Subjects: Patients with dyslipidemia over 50 years of age who received statin treatmen for at least 2 months


Recruitment information / eligibility

Status Recruiting
Enrollment 112
Est. completion date August 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: 1. Patients with dyslipidemia over 50 years of age who received statin treatmen for at least 2 months 2. Written informed consent to participate in the trial Exclusion Criteria: 1. History of previous hypersensitivity reaction to other statins, including rosuvastatin 2. patients with acute arterial disease within 3 months 3. Uncontrolled Hypertensive Patients defined as SBP =180 mm Hg and DBP =110 mm Hg, respectively 4. Uncontrolled diabetes mellitus (HbA1c > 9%) 5. Uncontrolled hypothyroidism defined as TSH >1.5 within the last 6 months 6. Taking other lipid lowering agent except statins 7. History of statin-induced myopathy, rhabdomyolysis 8. Patients with severe hepatic or renal dysfunction 9. BMI (body mass index) > 40 kg/m2 10. history of galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rosuvastatin Immediate-Release Tablet (IRT) 10mg
Rosuvastatin Immediate-Release Tablet (IRT) 10mg
Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg

Locations

Country Name City State
Korea, Republic of Division of Cardiology, Department of Internal Medicine, Yonsei Univerisity, Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (3)

Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001 Sep 1;88(5):504-8. doi: 10.1016/s0002-9149(01)01727-1. — View Citation

Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, Kim KY, Jeong MH, Chae JK, Oh SK, Seong IW. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med. 2010 Mar;25(1):27-35. doi: 10.3904/kjim.2010.25.1.27. Epub 2010 Feb 26. — View Citation

Zhang L, Zhang S, Yu Y, Jiang H, Ge J. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations. Herz. 2020 Sep;45(6):594-602. doi: 10.1007/s00059-018-4767-2. Epub 2018 Nov 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in LDL-C level from Baseline after treatment of each formulation for 8 week Week 0, 8, 16
Secondary Change in Total Cholesterol (TC) from Baseline after treatment of each formulation for 8 week Week 0, 8, 16
Secondary Change in High-density lipoprotein (HDL) from Baseline after treatment of each formulation for 8 week Week 0, 8, 16
Secondary Change in Triglycerides (TG) from Baseline after treatment of each formulation for 8 week Week 0, 8, 16
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT02837367 - Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People N/A
Active, not recruiting NCT02600338 - Meta-analyses of the Effect of Legumes on Blood Pressure N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01764295 - Clinical Study for Patients With Hypertension Associated With Dyslipidemia Phase 3
Completed NCT01531062 - Effect of Nigella Sativa on Lipid Profiles in Elderly Phase 2
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Terminated NCT01414166 - Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) Phase 3
Recruiting NCT01670968 - HIV Reverse Cholesterol Transport Study
Completed NCT00977288 - A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) Phase 2
Completed NCT01285544 - The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia Phase 4
Completed NCT00768274 - Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol Phase 1/Phase 2
Withdrawn NCT00664287 - Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) Phase 3
Completed NCT01483235 - Reduced Cardiac Rehabilitation Program N/A
Completed NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Phase 3
Completed NCT00309777 - Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Phase 3